2902. Dalbavancin Use in Bone and Joint Infections

BACKGROUND: Dalbavancin (DAL) is currently FDA-approved to treat acute bacterial skin and soft tissue infections. Use of DAL for off-label indications have been reported in difficult-to-treat infections, including osteomyelitis and prosthetic joint infections. Once weekly DAL dosing is an attractive...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanikommu, Srivani, Alderson, Liam P, Bailey, Brett, Stambough, Jeffrey, Stronach, Benjamin, Mears, Simon, Dare, Ryan K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678224/
http://dx.doi.org/10.1093/ofid/ofad500.173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678224/
http://dx.doi.org/10.1093/ofid/ofad500.173

Ejemplares similares